SAKK 08/14 substudy: Serum metabolomics identifies potential prognostic biomarkers in metastatic castration-resistant prostate cancer

Genitourinary Cancer

Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [(177)Lu]Lu-PSMA-617

Eur Urol

Fettke H, Kostos L, Docanto M, Bukczynska P, Ng N, Medhurst E, Awad M, Buteau JP, Eliceiry SC, Manoharan S, Foroughi S, Steen J, Nguyen-Dumont T, Hofman MS, Azad AA, ProsTIC Registry Investigators

doi: 10.1016/j.eururo.2025.08.015

Genitourinary Cancer

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

Int J Cancer

Incorvaia L, Santini D, Matrana MR, Maruzzo M, Kopp RM, Antonuzzo L, Bracarda S, Tural D, Procopio G, Bourlon MT, Caffo O, Zapata Laguado MI, Di Maio M, Maiorano BA, Conteduca V, Rossetti S, Lipari H, Büttner T, Rizzo M, Ürün Y, Messina C, Marques Monteiro FS, Soares A, Puglisi M, Principi A, Lai E, Mammone G, Stellato M, Depetris I, Bazan Russo TD, Spricido IY, Gismondi CBL, Massari F, Pavan N, Santoni M, Taha T

doi: 10.1002/ijc.70679

Genitourinary Cancer

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer

Prostate Cancer Prostatic Dis

Morgans AK, Wallis CJD, Halabi S, Armstrong AJ, Adorjan P, Ghadessi M, Verholen F, Grimm MO

doi: 10.1038/s41391-026-01076-w

Genitourinary Cancer

Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer

Clin Cancer Res

Jani CT, Tran E, Zhang N, Tsai J, Dong J, Bucheit L, Pan E, Panian J, Chen YW, McKay RR

doi: 10.1158/1078-0432.CCR-25-3071

Genitourinary Cancer

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

Prostate

Yellanki M, La J, Elbers DC, Do NV, Paller CJ, Fillmore NR, Schoen MW

doi: 10.1002/pros.70247

Genitourinary Cancer

Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial

Lancet Oncol

Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, Herrmann K, Roubaud G, Nagarajah J, Fleming M, Lewis B, Nordquist L, Carnahan N, Ghebremariam S, Hertelendi M, Castellano D, Sartor O

doi: 10.1016/S1470-2045(25)00189-5

Genitourinary Cancer

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer

Ann Oncol

Gillessen S, Gallardo E, Choudhury A, Saad F, Soares A, Loriot Y, McDermott R, Rodriguez-Vida A, Isaacsson Velho P, Nolè F, Cruz F, Roumeguere T, Daugaard G, Yamamura R, Bompas E, Maroto P, Veiga FG, Skoneczna I, Martins da Trindade K, Mavignier Carcano F, Lecouvet F, Coens C, Poncet C, Fournier B, Tombal B

doi: 10.1016/j.annonc.2026.02.009

Genitourinary Cancer

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1

J Clin Oncol

Taplin ME, Riaz IB, Rumble RB, Naqvi SAA, Hope TA, Dias MF, He H, Hotte SJ, Emamekhoo H, Murad MH, Celano P, Kungel TM, Hentzen S, Serzan MT, Parikh RA

doi: 10.1200/JCO-25-02693

Genitourinary Cancer

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis

Prostate Cancer Prostatic Dis

Yu EY, Suzuki H, Pieczonka CM, Gotto G, Briganti A, Luz M, Murphy D, Malone R, Hamilton J, Chan JE, Sieber P, Given RW, Hellmis E, Kretz T, Spiegelhalder P, Gómez-Caamaño A, Amela YM, Artignan X, Uemura H, Fujita N, Adorjan P, Ghadessi M, Verholen F, Armstrong AJ

doi: 10.1038/s41391-025-01047-7

Related content

Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [(177)Lu]Lu-PSMA-617

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer

Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis